References
- de Groot PM, Wu CC, Carter BW, et al. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220–233.
- Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–594.
- International association for the study of lung cancer 8th Edition of the TNM Classification for Lung Cancer. iaslc.org [Internet]; [ cited 2020 Aug]. Available from: https://www.iaslc.org/Portals/0/35348-cards-erx_combined_trap_card3_1_copy.pdf?ver=2019-05-22-154420-317
- Blandin Knight S, Crosbie PA, Balata H, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9):170070.
- Lu T, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943–953.
- Carbone DP, Gandara DR, Antonia SJ, et al. Non-Small-Cell Lung Cancer: role of the immune system and potential for immunotherapy. J Thorac Oncol. 2015;10(7):974–984.
- Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med. 2015;4(5):661–672.
- Planchard D, Popat S, Kerr K, et al. Metastatic Non-Small-Cell Lung Cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol; 2018 Accessed Aug 2020;29(suppl 4):iv192–iv237. Available from: https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer
- Hanna NH, Schneider BJ, Temin S, et al. Therapy for Stage IV Non–Small-Cell Lung Cancer without driver alterations: ASCO and OH (CCO) joint guideline update. J clin oncol. 2020;38(14):1608–1632.
- Carbone DP, Reck M. L Paz-Ares et al. First-line nivolumab in Stage IV or recurrent Non–Small-Cell Lung Cancer. N Engl J Med. 2017 June 22;376:2415–2426.
- Berardi R. KEYNOTE-024: goodbye to chemotherapy? J Thorac Dis. 2019;11(Suppl 3):S428–S432.
- Reck M, Rodríguez-Abreu D, Robinson AG, et al. OA14.01 KEYNOTE-024 3-year survival update: pembrolizumab vs platinum-based chemotherapy for advanced Non–Small-Cell Lung Cancer. J Thorac Oncol. 2019 Oct 01;14(10):S243.
- Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. LBA51 - KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%. Ann Oncol. 2020;31(suppl_4):S1142–S1215.
- KEYNOTE-042: pembrolizumab vs chemotherapy in previously untreated locally advanced or metastatic NSCLC with PD-L1 Expression ≥ 1%. ascopost.com [Internet]; [ cited 2020 Oct]. Available from: https://ascopost.com/News/59962
- Atezolizumab improves survival in high PD-L1 expressing NSCLC. onclive.com [Internet]; [ cited 2020 Oct]. Available from: https://www.onclive.com/view/atezolizumab-improves-survival-in-high-pd-l1-expressing-nsclc
- Remon J, Besse B, Soria JC. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med. 2017;15:55.
- Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive Non–Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823–1833.
- Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830.
- Atezolizumab as first-line treatment of metastatic NSCLC with high PD-L1 expression and no EGFR or ALK aberrations. ascopost.com [Internet]; [ cited 2020 Oct]. Available from: https://ascopost.com/issues/july-10-2020/atezolizumab-as-first-line-treatment-of-metastatic-nsclc-with-high-pd-l1-expression-and-no-egfr-or-alk-aberrations/
- Liu D, Jenkins RW, Sullivan RJ. Mechanisms of resistance to immune checkpoint blockade. Am J Clin Dermatol. 2019;20(1):41–54.
- Jenkins R, Barbie D, Flaherty K. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118:9–16.
- Rocco D, Gravara LD, Gridelli C. The new immunotherapy combinations in the treatment of advanced Non-Small Cell Lung Cancer: reality and perspectives. Curr Clin Pharmacol. 2020;15:11.
- Marmarelis ME, Aggarwal C. Combination immunotherapy in Non-small Cell Lung Cancer. Curr Oncol Rep. 2018 May 8;20(7):55.
- Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–443.
- Ramakrishnan R, Gabrilovich DI. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol Immunother. 2011;60(3):419–423.
- Heinhuis KM, Ros W, Kok M, et al. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30:219–235.
- Harris SJ, Brown J, Lopez J, et al. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med. 2016;13(2):171–193.
- Marshall HT, Djamgoz MBA. Immuno-oncology: emerging targets and combination therapies. Front Oncol. 2018 Aug 23;8:315.
- Villanueva N, Bazhenova L. New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Ther Adv Respir Dis. 2018;12:1753466618794133.
- Rocco D, Gregorc V, Della Gravara L, et al. New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials. Expert Opin Investig Drugs. 2020;29:1005–1023.
- Corrales L, Scilla K, Caglevic C, et al. Immunotherapy in lung cancer: a new age in cancer treatment. Adv Exp Med Biol. 2018;995:65–95.
- Juergens R, Hellmann M, Brahmer J et al. First-line nivolumab plus platinum-based doublet chemotherapy for advanced NSCLC: checkMate 012 3-year update
- Reck M, Borghaei H, O’Byrne KJ. Nivolumab plus ipilimumab in non-small-cell lung cancer. Future Oncol. 2019;15(19):1363–1383.
- Frontline nivolumab/ipilimumab combo improves OS in advanced NSCLC. onclive.com [Internet]; [ cited 2020 Oct]. Available from: https://www.onclive.com/view/frontline-nivolumab-ipilimumab-combo-improves-os-in-advanced-nsclc
- First-line nivolumab plus chemotherapy did not meet the primary endpoint of overall survival in non-squamous NSCLC. esmo.org [Internet]; [ cited 2020 Aug]. Available from: https://www.esmo.org/meetings/past-meetings/esmo-immuno-oncology-congress-2019/congress-coverage/news-press-releases/first-line-nivolumab-plus-chemotherapy-did-not-meet-the-primary-endpoint-of-overall-survival-in-non-squamous-nsclc
- Bristol-myers squibb provides update on Part 2 of CHECKMATE −227. bms.com; press release [Internet]; [ cited 2020 Aug]. Available from: https://news.bms.com/press-release/rd-news/bristol-myers-squibb-provides-update-part-2-checkmate-227
- Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010;25(6):601–613.
- Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burdenN Engl J Med. 2018. DOI:10.1056/NEJMoa1801946
- BMS press release [internet] bristol-myers squibb provides update on the ongoing regulatory review of opdivo plus low-dose yervoy in first-line lung cancer patients with tumor mutational Burden ≥10 mut/Mb; [ cited 2020 Aug]. Available from: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-provides-update-ongoing-regulatory-review
- FDA approves opdivo (nivolumab) + Yervoy (ipilimumab) as first-line treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1≥1%. drugs.com [Internet]; [ cited 2020 Aug]. Available from: https://www.drugs.com/newdrugs/fda-approves-opdivo-nivolumab-yervoy-ipilimumab-first-line-patients-metastatic-non-small-cell-lung-5239.html
- FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC. fda.gov [Internet]; [ cited 2020 Aug]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc
- NCCN clinical practice guidelines in oncology Non-Small Cell Lung Cancer. NCCN.org [internet]; [ cited 2020 Aug]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
- Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378:2078–2092.
- Gadgeel SM, Garassino MC, Esteban E, et al. KEYNOTE-189: updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. J clin oncol. 2019;37(15_suppl):9013.
- Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for Squamous Non–Small-Cell Lung Cancer. N Engl J Med. 2018;379:2040–2051.
- Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301.
- Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):P387–401.
- Hanna NH, Schneider BJ, Temin S, et al. Therapy for Stage IV Non–Small-Cell Lung Cancer without driver alterations: ASCO and OH (CCO) joint guideline update. J clin oncol. 2020 May 10;38(14):1608–1632.
- Villalobos P, Wistuba II. Lung cancer biomarkers. Hematol Oncol Clin North Am. 2017;31(1):13–29.
- Mathew M, Safyan RA, Shu CA. PD-L1 as a biomarker in NSCLC: challenges and future directions. Ann Transl Med. 2017;5(18):375.
- Remon J, Collazo A, Jimenez B. CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer. TCR. 2020 Apr;9(4). DOI:10.21037/tcr.2020.03.09
- Sholl LM, Hirsch FR, Hwang D, et al. The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the international association for the study of lung cancer pathology committee. J Thorac Oncol. 2020 Sep;15(9):1409–1424. DOI:10.1016/j.jtho.2020.05.019.
- Metro G, Signorelli D. Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions? Lung Cancer Manage. 2020 Jan 16;8(4):LMT18.
- Gravara LD, Battiloro C, Cantile R, et al. Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach? Lung Cancer Manage. 2020 Feb 12;9(1):LMT22.
- Hochmair MJ. Resistance to chemoimmunotherapy in non-small-cell lung cancer. Cancer Drug Resist. 2020;3:445–453.